Racial/ethnic residential segregation and the availability of opioid and substance use treatment facilities in US counties, 2009–2019

DiNardi, Michael; Swann, William L.; Kim, Serena

doi:10.1016/j.ssmph.2022.101289

Cited by 3 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29 This treatment gap is largely attributed to complex intersections of determinants of health and geographical region, with a dearth of office-based buprenorphine availability for Black individuals. 30 Furthermore, even with the increase in availability and utilization of telemedicine in recent years, women are less likely to engage in telehealth, and 10% of women report experiencing discrimination based on age, sex, race or another demographic characteristic from healthcare providers. 31,32 Comprehensive evaluation of treatment, especially among vulnerable groups with a thorough understanding of barriers for women and racially minoritized populations, is strongly needed.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, only 5% of individuals with an opioid use disorder have access to methadone 29 . This treatment gap is largely attributed to complex intersections of determinants of health and geographical region, with a dearth of office-based buprenorphine availability for Black individuals 30 . Furthermore, even with the increase in availability and utilization of telemedicine in recent years, women are less likely to engage in telehealth, and 10% of women report experiencing discrimination based on age, sex, race or another demographic characteristic from healthcare providers 31,32 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Substance Use Overdose Deaths Among Black and Indigenous Women in Wisconsin: A Review of Death Certificate Data From 2018 to 2020

Lopez,

Luebke,

Redner

et al. 2024

J Addict Med

View full text Add to dashboard Cite

Objectives We are in the midst of an overdose epidemic that has grown during the concurrent COVID-19 pandemic. In Wisconsin, overdose deaths increased 11-fold from 2000 to 2020, with over 1200 deaths in 2020. Because of disparities in substance use initiation, relapse, and treatment success among racially minoritized women, this study's purpose was to investigate overdose death rates among Black and Indigenous women in Wisconsin from 2018 to 2020. Methods Overdose death rates were examined under the following parameters: sex, race (Black, Indigenous, White), age, year, and manner of death. Logistic regression analysis was also conducted looking at death count data, with race, age, and year as potential predictor variables. Results Death rates (per 100,000) in 2018 were 14.1 (12.6–15.5) for White women, 20.8 (14.7–26.9) for Black women, and 26.5 (10.0–42.9) for Indigenous women; these rates increased in 2020 to 16.4 (14.8–17.9), 32.5 (25.0–40.0), and 59.9 (35.8–84.0) for White, Black, and Indigenous women, respectively. Regression findings illustrated that being Black or Indigenous and aged 15 to 44 or 45 to 64 years were significantly more likely to die from most causes of death (any drug, any opioid, prescription opioid, heroin, synthetic opioids, and cocaine; adjusted odds ratios > 1.25, Ps < 0.001). Conclusions This study confirms that deaths in Wisconsin are disproportionately higher in female minoritized populations. Understanding the complex intricacies between the impacts of the COVID-19 pandemic coupled with barriers to treatment access or acceptability in these populations is urgently needed. It will take a multipronged approach to address the overdose epidemic and better serve these marginalized, vulnerable populations.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Substance Use Overdose Deaths Among Black and Indigenous Women in Wisconsin: A Review of Death Certificate Data From 2018 to 2020

Lopez,

Luebke,

Redner

et al. 2024

J Addict Med

View full text Add to dashboard Cite

show abstract

Spatial access to buprenorphine-waivered prescribers in the HEALing communities study: Enhanced 2-step floating catchment area analyses in Massachusetts, Ohio, and Kentucky

Shrestha

Lindstrom

Harris

et al. 2023

Journal of Substance Use and Addiction Treatment

View full text Add to dashboard Cite

Barriers to opioid use disorder treatment: A comparison of self-reported information from social media with barriers found in literature

Bremer

Plaisance

Walker

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

IntroductionMedications such as buprenorphine and methadone are effective for treating opioid use disorder (OUD), but many patients face barriers related to treatment and access. We analyzed two sources of data—social media and published literature—to categorize and quantify such barriers.MethodsIn this mixed methods study, we analyzed social media (Reddit) posts from three OUD-related forums (subreddits): r/suboxone, r/Methadone, and r/naltrexone. We applied natural language processing to identify posts relevant to treatment barriers, categorized them into insurance- and non-insurance-related, and manually subcategorized them into fine-grained topics. For comparison, we used substance use-, OUD- and barrier-related keywords to identify relevant articles from PubMed published between 2006 and 2022. We searched publications for language expressing fear of barriers, and hesitation or disinterest in medication treatment because of barriers, paying particular attention to the affected population groups described.ResultsOn social media, the top three insurance-related barriers included having no insurance (22.5%), insurance not covering OUD treatment (24.7%), and general difficulties of using insurance for OUD treatment (38.2%); while the top two non-insurance-related barriers included stigma (47.6%), and financial difficulties (26.2%). For published literature, stigma was the most prominently reported barrier, occurring in 78.9% of the publications reviewed, followed by financial and/or logistical issues to receiving medication treatment (73.7%), gender-specific barriers (36.8%), and fear (31.5%).ConclusionThe stigma associated with OUD and/or seeking treatment and insurance/cost are the two most common types of barriers reported in the two sources combined. Harm reduction efforts addressing barriers to recovery may benefit from leveraging multiple data sources.

show abstract

Racial/ethnic residential segregation and the availability of opioid and substance use treatment facilities in US counties, 2009–2019

Cited by 3 publications

References 39 publications

Substance Use Overdose Deaths Among Black and Indigenous Women in Wisconsin: A Review of Death Certificate Data From 2018 to 2020

Substance Use Overdose Deaths Among Black and Indigenous Women in Wisconsin: A Review of Death Certificate Data From 2018 to 2020

Spatial access to buprenorphine-waivered prescribers in the HEALing communities study: Enhanced 2-step floating catchment area analyses in Massachusetts, Ohio, and Kentucky

Barriers to opioid use disorder treatment: A comparison of self-reported information from social media with barriers found in literature

Contact Info

Product

Resources

About